Sino Biopharm completed enrollment: Sino Biopharmaceutical stock is 33.08 percent below its high
Published on 10/13/2026 at 06:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- Sino Biopharm completed enrollment in a Phase III registrational trial on October 8, 2026.
- First-half 2026 revenue rose 10.60 percent to RMB 19.44 billion.
- Innovation drug and out-licensing revenue increased 44.30 percent to RMB 8.79 billion.
- Sino Biopharmaceutical stock stood 33.08 percent below its HKD 7.98 52-week high on October 13, 2026.
Sino Biopharm completed enrollment in a Phase III registrational trial on October 8, 2026, according to Goodinvest. Sino Biopharmaceutical stock stood 33.08 percent below its HKD 7.98 52-week high at HKD 5.34 on October 13, 2026.
Three milestones shape the pipeline
The October 8 trial update followed an interim report for the six months ended June 30, 2026. Futubull reported revenue of RMB 19.44 billion, up 10.60 percent year over year, while profit attributable to equity holders reached RMB 3.43 billion, up 1.40 percent.
On September 28, 2026, Sino Biopharmaceutical subsidiary CTTQ entered a biosimilar collaboration with STADA covering TQB3570. Fineline Cube said the agreement includes up to EUR 53.00 million in milestone payments and options for up to three additional molecules.
On September 24, 2026, FilingReader reported that innovative drug and out-licensing revenue rose 44.30 percent to RMB 8.79 billion, equal to 45.20 percent of group revenue. The board also declared an interim dividend of HKD 0.07 per share.
What does enrollment add to the pipeline?
Completion of all subject enrollment in the Phase III TQC3721 inhalation suspension trial adds a late-stage development milestone to the group's respiratory pipeline, while the first-half numbers show a larger contribution from innovative medicines and licensing. The 44.30 percent increase in that revenue stream exceeded the 10.60 percent growth of total revenue.
Stock stays below its yearly high
Finance data put Sino Biopharmaceutical's market capitalization at HKD 95.1 billion on October 13, 2026, with a 52-week range of HKD 4.19 to HKD 7.98. The stock's position 33.08 percent below the high contrasts with the company's 45.20 percent revenue share from innovative drugs and out-licensing in the first half.
The latest Lang & Schwarz quote was EUR 0.62 on October 12, 2026 at 10:57 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Sino Biopharm stock.
Sino Biopharmaceutical at a glance
- Company: Sino Biopharmaceutical Limited
- ISIN: KYG8167W1380
- Ticker: 1177.HK
- Primary exchange: HKEX
- Price Lang & Schwarz (as of October 12, 2026, 10:57 p.m. CEST): EUR 0.62
- Market capitalization: HKD 95.1 billion (as of October 13, 2026)
- 52-week range: HKD 4.19-7.98 (as of October 13, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals, Biotechnology & Life Sciences
Market context: Latest market reports.
